New drugs showing promise for CLL patients at ASH 2014: A discussion between Prof John Gribben and Prof Peter Hillmen

Published on

Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL) that were presented at the 2014 American Society of Hematology (ASH) Annual Meeting. Balancing efficacy versus toxicity is important when choosing a treatment strategy and there is reference to the new CLL10 study. Anti-CD1 monoclonal antibody therapy after completing chemotherapy, the 17p deletion, allogeneic transplants and a 'chemo-free' approach are also considered. Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network  

View more programs featuring

Join Our Community Register for Events Read Our Latest Blog

Page last updated on January 26, 2016